Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology

Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational and experimental methods in an iterative way to gain a comprehensive, unbiased understanding of disease processes to inform effective therapeutic strategies. We report the implementation of QSP to Huntington’s Disease, with the application of a chemogenomics platform to identify strategies to protect neuronal cells from mutant huntingtin induced death. Using the STHdhQ111 cell model, we investigated the protective effects of small molecule probes having diverse canonical modes-of-action to infer pathways of neuronal cell protection connected to drug mechanism. Several mechanistically diverse protective probes were identified, most of which showed less than 50% efficacy. Specific combinations of these probes were synergistic in enhancing efficacy. Computational analysis of these probes revealed a convergence of pathways indicating activation of PKA. Analysis of phospho-PKA levels showed lower cytoplasmic levels in STHdhQ111 cells compared to wild type STHdhQ7 cells, and these levels were increased by several of the protective compounds. Pharmacological inhibition of PKA activity reduced protection supporting the hypothesis that protection may be working, in part, through activation of the PKA network. The systems-level studies described here can be broadly applied to any discovery strategy involving small molecule modulation of disease phenotype.

• Publication year

  2017

• Venue

  Scientific Reports

• Publication date

  2017-12-19

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/s41598-017-17378-yPMID 29259176PMCID 5736652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biologically Relevant Heterogeneity: Metrics and Practical Insights

  2017cited by this paper
• A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens.

  2016cited by this paper
• A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine

  2016cited by this paper
• Chemical proteomics approaches for identifying the cellular targets of natural products

  2016cited by this paper
• A Human Brain Microphysiological System Derived from Induced Pluripotent Stem Cells to Study Neurological Diseases and Toxicity

  2016cited by this paper
• The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.

  2016cited by this paper
• A dynamic interface between ubiquitylation and cAMP signaling

  2015cited by this paper
• Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

  2015cited by this paper
• Using quantitative systems pharmacology for novel drug discovery

  2015cited by this paper
• BalestraWeb: efficient online evaluation of drug–target interactions

  2014cited by this paper
• Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery

  2014cited by this paper
• Systematic identification of signaling pathways with potential to confer anticancer drug resistance

  2014cited by this paper
• Inhibition of mitochondrial protein import by mutant huntingtin

  2014cited by this paper
• A New Bliss Independence Model to Analyze Drug Combination Data

  2014cited by this paper
• Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance

  2013cited by this paper
• Huntington’s Disease: The Past, Present, and Future Search for Disease Modifiers

  2013cited by this paper
• Predicting Drug–Target Interactions Using Probabilistic Matrix Factorization

  2013cited by this paper
• Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration.

  2013cited by this paper
• Distilling pathophysiology from complex disease genetics.

  2013cited by this paper
• Target identification and mechanism of action in chemical biology and drug discovery.

  2013cited by this paper
• The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so.

  2013cited by this paper
• Regulation of Feedback between Protein Kinase A and the Proteasome System Worsens Huntington's Disease

  2012cited by this paper
• The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

  2011cited by this paper
• Regulation of Nuclear PKA revealed by spatiotemporal manipulation of cAMP

  2011cited by this paper
• Molecular mechanisms and potential therapeutical targets in Huntington's disease.

  2010cited by this paper
• Target profiling of small molecules by chemical proteomics.

  2009cited by this paper
• Pharmacological PKA Inhibition: All May Not Be What It Seems

  2008cited by this paper
• Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease

  2008cited by this paper
• Comparison of shape-matching and docking as virtual screening tools.

  2007cited by this paper
• Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

  2006cited by this paper
• Subcellular dynamics of protein kinase A activity visualized by FRET-based reporters.

  2006cited by this paper
• Classification of cell death: recommendations of the Nomenclature Committee on Cell Death

  2005cited by this paper
• Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

  2005cited by this paper
• Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract

  2005cited by this paper
• Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

  2005cited by this paper
• Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments.

  2004cited by this paper
• Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease

  2003cited by this paper
• Carbonic anhydrase inhibitors

  2003cited by this paper
• Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

  2000cited by this paper
• Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

  2000cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

  2000cited by this paper
• Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist

  1999cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• The search for synergy: a critical review from a response surface perspective.

  1995cited by this paper
• Forskolin photoaffinity labels with specificity for adenylyl cyclase and the glucose transporter.

  1991cited by this paper
• Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Papaverine-induced inhibition of phosphodiesterase activity in various mammalian tissues.

  1971cited by this paper
• THE TOXICITY OF POISONS APPLIED JOINTLY1

  1939cited by this paper

• Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective

  2025cites this paper
• Pharmacokinetics–Pharmacodynamics Modeling for Evaluating Drug–Drug Interactions in Polypharmacy: Development and Challenges

  2024cites this paper
• HD_BPMDS: a curated binary pattern multitarget dataset of Huntington’s disease–targeting agents

  2023cites this paper
• A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development

  2022cites this paper
• Hallmarks of neurodegenerative disease: A systems pharmacology perspective

  2022cites this paper
• Systems Pharmacology: Enabling Multidimensional Therapeutics

  2021cites this paper
• Predicting the Effects of Drug Combinations Using Probabilistic Matrix Factorization

  2021cites this paper
• A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity

  2021cites this paper
• Human biomimetic liver microphysiology systems in drug development and precision medicine

  2020cites this paper
• Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision

  2020cites this paper
• QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics

  2020cites this paper
• Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance

  2020cites this paper
• Neuronal population models reveal specific linear conductance controllers sufficient to rescue preclinical disease phenotypes

  2020cites this paper
• Systems pharmacology

  2020cites this paper
• Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology.

  2019cites this paper
• Systems pharmacology approach reveals the antiinflammatory effects of Ampelopsis grossedentata on dextran sodium sulfate-induced colitis

  2018cites this paper
• Quantitative Systems Pharmacological Analysis of Drugs of Abuse Reveals the Pleiotropy of Their Targets and the Effector Role of mTORC1

  2018cites this paper
• Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

  2018cites this paper
• A Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease Phenotypes.

  2018cites this paper